Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report: Hepatitis E during vedolizumab therapy in IBD

R. L. Goetgebuer; G. M.C. Masclee; A. A. van der Eijk; C. J. van der Woude; R. A. de Man; A. C. de Vries

doi:10.1016/j.clinre.2022.101948

Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report: Hepatitis E during vedolizumab therapy in IBD

R. L. Goetgebuer^*, G. M.C. Masclee, A. A. van der Eijk, C. J. van der Woude, R. A. de Man, A. C. de Vries

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

3 Downloads (Pure)

Abstract

We present a 49 year old female patient with Crohn's disease (CD) in remission on vedolizumab therapy who experienced a symptomatic, though benign, course of acute hepatitis E. Routine blood tests showed substantial elevation of liver enzymes and polymerase chain reaction (PCR) testing confirmed hepatitis E virus (HEV) infection. Vedolizumab therapy was paused, liver enzymes improved three weeks after infection and normalized after six months. The patient recovered completely from mild symptoms. This case shows that hepatitis E is a potential cause of acute hepatitis during vedolizumab therapy, and in this case the infection has run a benign course.

Original language	English
Article number	101948
Journal	Clinics and Research in Hepatology and Gastroenterology
Volume	46
Issue number	7
DOIs	https://doi.org/10.1016/j.clinre.2022.101948
Publication status	Published - 1 Aug 2022

Bibliographical note

Acknowledgements: We would like to thank the patient of this case report. She gave us permission to write down her disease course and she was very helpful in sharing her patient history. We did not receive any funding for this study. We would like to thank Kabir Paul Ravindra for checking English grammar and syntax.

Publisher Copyright: © 2022 The Author(s)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clinre.2022.101948Licence: CC BY

Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's diseaseFinal published version, 357 KBLicence: CC BY

Cite this

Goetgebuer, R. L., Masclee, G. M. C., van der Eijk, A. A., van der Woude, C. J., de Man, R. A., & de Vries, A. C. (2022). Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report: Hepatitis E during vedolizumab therapy in IBD. Clinics and Research in Hepatology and Gastroenterology, 46(7), [101948]. https://doi.org/10.1016/j.clinre.2022.101948

@article{78ada17a10314f24ad5c307901aaab5d,

title = "Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report: Hepatitis E during vedolizumab therapy in IBD",

abstract = "We present a 49 year old female patient with Crohn's disease (CD) in remission on vedolizumab therapy who experienced a symptomatic, though benign, course of acute hepatitis E. Routine blood tests showed substantial elevation of liver enzymes and polymerase chain reaction (PCR) testing confirmed hepatitis E virus (HEV) infection. Vedolizumab therapy was paused, liver enzymes improved three weeks after infection and normalized after six months. The patient recovered completely from mild symptoms. This case shows that hepatitis E is a potential cause of acute hepatitis during vedolizumab therapy, and in this case the infection has run a benign course.",

author = "Goetgebuer, {R. L.} and Masclee, {G. M.C.} and {van der Eijk}, {A. A.} and {van der Woude}, {C. J.} and {de Man}, {R. A.} and {de Vries}, {A. C.}",

note = "Acknowledgements: We would like to thank the patient of this case report. She gave us permission to write down her disease course and she was very helpful in sharing her patient history. We did not receive any funding for this study. We would like to thank Kabir Paul Ravindra for checking English grammar and syntax. Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = aug,

day = "1",

doi = "10.1016/j.clinre.2022.101948",

language = "English",

volume = "46",

journal = "Clinics and Research in Hepatology and Gastroenterology",

issn = "2210-7401",

publisher = "Elsevier Masson",

number = "7",

}

Goetgebuer, RL, Masclee, GMC, van der Eijk, AA , van der Woude, CJ , de Man, RA & de Vries, AC 2022, 'Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report: Hepatitis E during vedolizumab therapy in IBD', Clinics and Research in Hepatology and Gastroenterology, vol. 46, no. 7, 101948. https://doi.org/10.1016/j.clinre.2022.101948

Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease : A case report: Hepatitis E during vedolizumab therapy in IBD. / Goetgebuer, R. L.; Masclee, G. M.C.; van der Eijk, A. A. et al.

In: Clinics and Research in Hepatology and Gastroenterology, Vol. 46, No. 7, 101948, 01.08.2022.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease

T2 - A case report: Hepatitis E during vedolizumab therapy in IBD

AU - Goetgebuer, R. L.

AU - Masclee, G. M.C.

AU - van der Eijk, A. A.

AU - van der Woude, C. J.

AU - de Man, R. A.

AU - de Vries, A. C.

N1 - Acknowledgements: We would like to thank the patient of this case report. She gave us permission to write down her disease course and she was very helpful in sharing her patient history. We did not receive any funding for this study. We would like to thank Kabir Paul Ravindra for checking English grammar and syntax. Publisher Copyright: © 2022 The Author(s)

PY - 2022/8/1

Y1 - 2022/8/1

N2 - We present a 49 year old female patient with Crohn's disease (CD) in remission on vedolizumab therapy who experienced a symptomatic, though benign, course of acute hepatitis E. Routine blood tests showed substantial elevation of liver enzymes and polymerase chain reaction (PCR) testing confirmed hepatitis E virus (HEV) infection. Vedolizumab therapy was paused, liver enzymes improved three weeks after infection and normalized after six months. The patient recovered completely from mild symptoms. This case shows that hepatitis E is a potential cause of acute hepatitis during vedolizumab therapy, and in this case the infection has run a benign course.

AB - We present a 49 year old female patient with Crohn's disease (CD) in remission on vedolizumab therapy who experienced a symptomatic, though benign, course of acute hepatitis E. Routine blood tests showed substantial elevation of liver enzymes and polymerase chain reaction (PCR) testing confirmed hepatitis E virus (HEV) infection. Vedolizumab therapy was paused, liver enzymes improved three weeks after infection and normalized after six months. The patient recovered completely from mild symptoms. This case shows that hepatitis E is a potential cause of acute hepatitis during vedolizumab therapy, and in this case the infection has run a benign course.

UR - http://www.scopus.com/inward/record.url?scp=85133266323&partnerID=8YFLogxK

U2 - 10.1016/j.clinre.2022.101948

DO - 10.1016/j.clinre.2022.101948

M3 - Article

C2 - 35659604

AN - SCOPUS:85133266323

VL - 46

JO - Clinics and Research in Hepatology and Gastroenterology

JF - Clinics and Research in Hepatology and Gastroenterology

SN - 2210-7401

IS - 7

M1 - 101948

ER -

Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report: Hepatitis E during vedolizumab therapy in IBD

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this